Physostigmine (English Wikipedia)

"Therapeutics". Alzheimer Research Forum. This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials.

archive.org

Potter SO (1893). A Handbook of Materia Medica, Pharmacy and Therapeutics. London: P. Blakiston's. p. 53.
Katzung BG, Masters S, Trever A (2009). Basic and Clinical Pharmacology. McGraw Hill. p. 110. ISBN 978-0-07-160405-5.
Roberts MF, Wink M (1998). Alkaloids: Biochemistry, Ecology, and Medicinal Applications. Plenum Press. p. 38. ISBN 978-1-4419-3263-1.

clinicalkey.com

Dean AJ, Lee DC (2019). "67". Roberts and Hedges' Clinical Procedures in Emergency Medicine and Acute Care (7th ed.). ClinicalKey. ISBN 9780323354783. Retrieved December 21, 2022.
Lee CK (2021). "30". Harriet Lane Handbook (22nd ed.). Elsevier. ISBN 9780323674072. Retrieved December 21, 2022.

doi.org

Moore PW, Rasimas JJ, Donovan JW (March 2015). "Physostigmine is the antidote for anticholinergic syndrome". Journal of Medical Toxicology. 11 (1): 159–160. doi:10.1007/s13181-014-0442-z. PMC 4371033. PMID 25339374.
Traub SJ, Nelson LS, Hoffman RS (2002). "Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: a review". Journal of Toxicology. Clinical Toxicology. 40 (6): 781–787. doi:10.1081/CLT-120015839. PMID 12475191. S2CID 11134665.
Zvosec DL, Smith SW, Litonjua R, Westfal RE (2007). "Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review". Clinical Toxicology. 45 (3): 261–265. doi:10.1080/15563650601072159. PMID 17453877. S2CID 39337739.
Scharman EJ, Erdman AR, Wax PM, Chyka PA, Caravati EM, Nelson LS, et al. (19 January 2006). "Diphenhydramine and dimenhydrinate poisoning: an evidence-based consensus guideline for out-of-hospital management". Clinical Toxicology. 44 (3): 205–223. doi:10.1080/15563650600585920. PMID 16749537. S2CID 702353.
Christodoulou C, MacAllister WS, McLinskey NA, Krupp LB (2008). "Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?". CNS Drugs. 22 (2): 87–97. doi:10.2165/00023210-200822020-00001. PMID 18193921. S2CID 37820092.
Coelho F, Birks J (2001). "Physostigmine for Alzheimer's disease". The Cochrane Database of Systematic Reviews. 2001 (2): CD001499. doi:10.1002/14651858.CD001499. PMC 8078195. PMID 11405996.
Mehta M, Adem A, Sabbagh M (2012). "New acetylcholinesterase inhibitors for Alzheimer's disease". International Journal of Alzheimer's Disease. 2012: 728983. doi:10.1155/2012/728983. PMC 3246720. PMID 22216416.
Sienkiewicz-Jarosz H, Maciejak P, Krzaścik P, Członkowska AI, Szyndler J, Bidziński A, et al. (May 2003). "The effects of central administration of physostigmine in two models of anxiety". Pharmacology, Biochemistry, and Behavior. 75 (2): 491–496. doi:10.1016/S0091-3057(03)00141-2. PMID 12873642. S2CID 25107323.
McHardy SF, Wang HL, McCowen SV, Valdez MC (April 2017). "Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015)". Expert Opinion on Therapeutic Patents. 27 (4): 455–476. doi:10.1080/13543776.2017.1272571. PMID 27967267. S2CID 205767629.
King AM, Aaron CK (February 2015). "Organophosphate and carbamate poisoning". Emergency Medicine Clinics of North America. 33 (1): 133–151. doi:10.1016/j.emc.2014.09.010. PMID 25455666.
Somani SM, Kutty RK, Krishna G (October 1990). "Eseroline, a metabolite of physostigmine, induces neuronal cell death". Toxicology and Applied Pharmacology. 106 (1): 28–37. doi:10.1016/0041-008X(90)90102-Z. PMID 2251681.
Julian PL, Pikl J (1935). "Studies in the Indole Series. III. On the Synthesis of Physostigmine". Journal of the American Chemical Society. 57 (3): 539–544. doi:10.1021/ja01306a046.
Julian PL, Pikl J, Boggess D (1934). "Studies in the Indole Series. II. Alkylation of 1-Methyl-3-Formyloxindole and a Synthesis of the Basic Ring Structure of Physostigmine". Journal of the American Chemical Society. 56 (8): 1797–1801. doi:10.1021/ja01323a046.
Scheindlin S (February 2010). "Episodes in the story of physostigmine". Molecular Interventions. 10 (1): 4–10. doi:10.1124/mi.10.1.1. PMID 20124558.
Proudfoot A (2006). "The early toxicology of physostigmine: a tale of beans, great men and egos". Toxicological Reviews. 25 (2): 99–138. doi:10.2165/00139709-200625020-00004. PMID 16958557. S2CID 28243177.
Walker MB (1934). "Treatment of myasthenia gravis with physostigmine". Lancet. 1 (5779): 1200–1201. doi:10.1016/S0140-6736(00)94294-6.

mgauk.org

Johnston JD, Houston B (Autumn 2002). "Dr Mary Walker – A Pioneer in the Treatment of Myasthenia Gravis". MGA News. UK: The Myasthenia Gravis Association. Archived from the original on 5 September 2008. Retrieved 23 November 2008.

nih.gov

pubmed.ncbi.nlm.nih.gov

Moore PW, Rasimas JJ, Donovan JW (March 2015). "Physostigmine is the antidote for anticholinergic syndrome". Journal of Medical Toxicology. 11 (1): 159–160. doi:10.1007/s13181-014-0442-z. PMC 4371033. PMID 25339374.
Traub SJ, Nelson LS, Hoffman RS (2002). "Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: a review". Journal of Toxicology. Clinical Toxicology. 40 (6): 781–787. doi:10.1081/CLT-120015839. PMID 12475191. S2CID 11134665.
Zvosec DL, Smith SW, Litonjua R, Westfal RE (2007). "Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review". Clinical Toxicology. 45 (3): 261–265. doi:10.1080/15563650601072159. PMID 17453877. S2CID 39337739.
Scharman EJ, Erdman AR, Wax PM, Chyka PA, Caravati EM, Nelson LS, et al. (19 January 2006). "Diphenhydramine and dimenhydrinate poisoning: an evidence-based consensus guideline for out-of-hospital management". Clinical Toxicology. 44 (3): 205–223. doi:10.1080/15563650600585920. PMID 16749537. S2CID 702353.
Christodoulou C, MacAllister WS, McLinskey NA, Krupp LB (2008). "Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?". CNS Drugs. 22 (2): 87–97. doi:10.2165/00023210-200822020-00001. PMID 18193921. S2CID 37820092.
Coelho F, Birks J (2001). "Physostigmine for Alzheimer's disease". The Cochrane Database of Systematic Reviews. 2001 (2): CD001499. doi:10.1002/14651858.CD001499. PMC 8078195. PMID 11405996.
Mehta M, Adem A, Sabbagh M (2012). "New acetylcholinesterase inhibitors for Alzheimer's disease". International Journal of Alzheimer's Disease. 2012: 728983. doi:10.1155/2012/728983. PMC 3246720. PMID 22216416.
Sienkiewicz-Jarosz H, Maciejak P, Krzaścik P, Członkowska AI, Szyndler J, Bidziński A, et al. (May 2003). "The effects of central administration of physostigmine in two models of anxiety". Pharmacology, Biochemistry, and Behavior. 75 (2): 491–496. doi:10.1016/S0091-3057(03)00141-2. PMID 12873642. S2CID 25107323.
McHardy SF, Wang HL, McCowen SV, Valdez MC (April 2017). "Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015)". Expert Opinion on Therapeutic Patents. 27 (4): 455–476. doi:10.1080/13543776.2017.1272571. PMID 27967267. S2CID 205767629.
King AM, Aaron CK (February 2015). "Organophosphate and carbamate poisoning". Emergency Medicine Clinics of North America. 33 (1): 133–151. doi:10.1016/j.emc.2014.09.010. PMID 25455666.
Somani SM, Kutty RK, Krishna G (October 1990). "Eseroline, a metabolite of physostigmine, induces neuronal cell death". Toxicology and Applied Pharmacology. 106 (1): 28–37. doi:10.1016/0041-008X(90)90102-Z. PMID 2251681.
Scheindlin S (February 2010). "Episodes in the story of physostigmine". Molecular Interventions. 10 (1): 4–10. doi:10.1124/mi.10.1.1. PMID 20124558.
Proudfoot A (2006). "The early toxicology of physostigmine: a tale of beans, great men and egos". Toxicological Reviews. 25 (2): 99–138. doi:10.2165/00139709-200625020-00004. PMID 16958557. S2CID 28243177.

ncbi.nlm.nih.gov

Moore PW, Rasimas JJ, Donovan JW (March 2015). "Physostigmine is the antidote for anticholinergic syndrome". Journal of Medical Toxicology. 11 (1): 159–160. doi:10.1007/s13181-014-0442-z. PMC 4371033. PMID 25339374.
Coelho F, Birks J (2001). "Physostigmine for Alzheimer's disease". The Cochrane Database of Systematic Reviews. 2001 (2): CD001499. doi:10.1002/14651858.CD001499. PMC 8078195. PMID 11405996.
Mehta M, Adem A, Sabbagh M (2012). "New acetylcholinesterase inhibitors for Alzheimer's disease". International Journal of Alzheimer's Disease. 2012: 728983. doi:10.1155/2012/728983. PMC 3246720. PMID 22216416.

rcpe.ac.uk

Doyle D (January 2009). "Sir Thomas Richard Fraser (1841–1920)" (PDF). JR Coll Physicians Edinb. 39: 283.

semanticscholar.org

api.semanticscholar.org

Traub SJ, Nelson LS, Hoffman RS (2002). "Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: a review". Journal of Toxicology. Clinical Toxicology. 40 (6): 781–787. doi:10.1081/CLT-120015839. PMID 12475191. S2CID 11134665.
Zvosec DL, Smith SW, Litonjua R, Westfal RE (2007). "Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review". Clinical Toxicology. 45 (3): 261–265. doi:10.1080/15563650601072159. PMID 17453877. S2CID 39337739.
Scharman EJ, Erdman AR, Wax PM, Chyka PA, Caravati EM, Nelson LS, et al. (19 January 2006). "Diphenhydramine and dimenhydrinate poisoning: an evidence-based consensus guideline for out-of-hospital management". Clinical Toxicology. 44 (3): 205–223. doi:10.1080/15563650600585920. PMID 16749537. S2CID 702353.
Christodoulou C, MacAllister WS, McLinskey NA, Krupp LB (2008). "Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?". CNS Drugs. 22 (2): 87–97. doi:10.2165/00023210-200822020-00001. PMID 18193921. S2CID 37820092.
Sienkiewicz-Jarosz H, Maciejak P, Krzaścik P, Członkowska AI, Szyndler J, Bidziński A, et al. (May 2003). "The effects of central administration of physostigmine in two models of anxiety". Pharmacology, Biochemistry, and Behavior. 75 (2): 491–496. doi:10.1016/S0091-3057(03)00141-2. PMID 12873642. S2CID 25107323.
McHardy SF, Wang HL, McCowen SV, Valdez MC (April 2017). "Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015)". Expert Opinion on Therapeutic Patents. 27 (4): 455–476. doi:10.1080/13543776.2017.1272571. PMID 27967267. S2CID 205767629.
Proudfoot A (2006). "The early toxicology of physostigmine: a tale of beans, great men and egos". Toxicological Reviews. 25 (2): 99–138. doi:10.2165/00139709-200625020-00004. PMID 16958557. S2CID 28243177.

web.archive.org

Johnston JD, Houston B (Autumn 2002). "Dr Mary Walker – A Pioneer in the Treatment of Myasthenia Gravis". MGA News. UK: The Myasthenia Gravis Association. Archived from the original on 5 September 2008. Retrieved 23 November 2008.

zenodo.org

Somani SM, Kutty RK, Krishna G (October 1990). "Eseroline, a metabolite of physostigmine, induces neuronal cell death". Toxicology and Applied Pharmacology. 106 (1): 28–37. doi:10.1016/0041-008X(90)90102-Z. PMID 2251681.